nasopharyngeal cancer
Conditions
Interventions
initial patients:cell injection
Relapsed patients:cell injection
Sponsors
Qi Hui
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: The patients who diagnosed as nasopharyngeal cancer with at least one measurable objective tumor index (through imaging diagnosis, such as CT, MRI examination, the maximum diameter of the lesion is measured = 1cm). No history of other tumors (excluding squamous cell carcinomas that have been cured by surgery). Males or females age between 18 to 75 (including 18 and 75). ECOG score 0 or 1. Expected survival time = 3 months. Blood, liver, kidney function, and blood clot laboratory tests meet the following criteria within 7 days before the treatment starts: white blood cells (WBC) = 3.5×10^9/L, platelets (PLT) =80×10^9/L, neutrophils (ANC) = 1.5 × 10^9/L, hemoglobin (HGB) = 90g/L, aspartate aminotransferase (AST) <2.5×upper limit of normal (the ULN) (liver metastases <5 × ULN), Alanine transaminase (ALT) <2.5xULN (liver metastasis<5 x ULN), total bilirubin (TIBC) <1.5xULN, serum creatinine (CR) <1.0 x ULN, prothrombin time, partial coagulation Live enzyme time, plasma fibrinogen, thrombin time were within the normal range. Subjects must take contraception during the entire study period. The subject has signed the informed consent form to understand the purpose of the study, the study steps and the study content and voluntarily participate in the study.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following conditions cannot participate in this study: 1. Patients with clinical symptoms of brain metastases (except radiotherapy control); 2. has active viral or bacterial infections and cannot be controlled with appropriate anti-infective treatments; 3. with HIV and syphilis, hepatitis B virus or hepatitis C virus infection; 4. suffering from mental illness or other conditions cannot cooperate with research treatmen; 5. Allergic to any of the components of the intervention; 6. rheumatic diseases; 7. has accepted the organ transplant; 8. Poor compliance; 9. Pregnant or nursing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival rate;complications;tumor control rate;life quality;Health economic index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Local recurrence rate ;distant metastases rate; | — |
Countries
China
Contacts
Public ContactQi Hui
Shenzhen People's Hospital
Outcome results
None listed